CHYM reported Q1 earnings after the close on May 6 that cleared every bar — EPS of $0.13 against a $0.03 estimate, revenue of $647M beating the $636M consensus — and then raised full-year sales guidance to $2.66B–$2.69B. The stock dropped 5.8% on the day regardless. That gap between a clean beat and a lower share price is the most interesting thing about this setup right now.
The options market had been telegraphing exactly this kind of ambivalent response. Call buyers dominated the tape heading into the print — the put/call ratio slid to 0.35, more than two standard deviations below its 20-day average of 0.41, the most call-heavy reading in months. Heading into results, traders were positioned for upside; the fact that the reaction was negative anyway signals the bar had been set high by an elevated stock. CHYM had gained 8% over the prior month, so the Q1 beat was arguably priced in before the first data point dropped.
Short interest tells a nuanced story here. Bears have been rebuilding since mid-April. SI jumped roughly 85% over the past month to 3.8% of the free float — still a modest absolute level, but the pace of accumulation is notable. Most of that move happened in a sharp step around April 10, when estimated short shares nearly doubled from roughly 7 million to 14 million in a single session. Since that jump, SI has traded sideways near 12–13 million shares. The lending market is not under pressure: availability is wide and cost to borrow remains low at 0.72% — though that rate has nearly doubled over the past week, worth monitoring. The ORTEX short score at 43.7 ranks in the bottom third of the universe, consistent with a market that is skeptical but not aggressively positioned.
The Street is broadly constructive, but the consensus was built almost entirely through a wave of fresh initiations. BMO Capital, Wells Fargo, and Compass Point all began coverage in April, each with bullish-to-neutral ratings and targets ranging from $25 to $30. Goldman Sachs carries a Buy with a $30 target. With the stock at $20.79, the mean target of $30.67 implies around 48% upside — and the analyst recommendation differential factor ranks in the 100th percentile, meaning the gap between current price and Street targets is as wide as it gets in this universe. The bull case rests on platform revenue growing at roughly 90% over recent quarters, driven by the MyPay initiative and member monetisation gains. Bears worry about credit model risks in a softer macro, competition from incumbent fintechs, and the risk that card network pricing could squeeze payments revenue.
Insider activity has been one-directional since IPO. Every transaction on record is a sale — the CEO, CFO, President, and most of the C-suite sold on February 17 at $19.69, roughly in line with where the stock trades today. The CEO also sold 50,000 shares in January near $28. In aggregate, net insider activity over the 90-day window reflects $9.5M in net sales. That is not unusual for a newly public company working through lock-up mechanics, but the pattern reinforces that those with the deepest view of the business have been consistent sellers. General Atlantic added around 2 million shares and Tiger Global added 1.7 million in the most recent institutional filings — one of the few incremental positive signals in the ownership picture.
The one comparable earnings reaction in the dataset — a March 13 print — saw CHYM fall 5.9% on the day and 11.4% over the subsequent five sessions. This week's drop is tracking the same first-day move. With the next earnings event scheduled for June 2, what to watch is whether the guidance raise ($2.66B–$2.69B vs. a prior $2.63B–$2.67B estimate consensus) is enough to attract fresh institutional buyers, or whether the combination of insider selling, rebuilding short interest, and a stock trading near its IPO-era lows keeps the gap between Street targets and market price stubbornly wide.
See the live data behind this article on ORTEX.
Open CHYM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
